Last updated: February 23, 2026
What is the scope of JP2016006085?
Patent JP2016006085 covers a pharmaceutical invention related to a novel compound, formulation, or method intended for specific therapeutic use. The patent was filed in Japan and published in 2016, claiming innovative aspects aimed at patent protection within its field.
The patent application appears to focus on the synthesis, composition, or use of a particular drug candidate or therapeutic method, often targeting a specific disease or condition. The scope includes:
- Chemical Composition: Specific chemical entities, derivatives, salts, or analogs purported to have therapeutic activity.
- Manufacturing Process: Methods for synthesizing or formulating the compound.
- Therapeutic Use: Claims covering the use of the compound for treating certain diseases, symptoms, or conditions.
The scope is confined by the claims, which define the legal boundaries of the patent rights.
How do the claims define the legal protection?
The claims precisely delineate what is protected. They generally fall into two categories:
Independent Claims
These broadly define the invention’s core element, such as:
- A chemical compound with a particular structure.
- A method of treatment involving administering the compound.
- A composition comprising the compound and excipient(s).
Dependent Claims
These narrow down the scope by adding specific features, such as:
- Particular substituents or functional groups.
- Specific dosages or formulations.
- Use in specific indications or patient populations.
The first claim, often an independent claim, creates the broadest protection, while subsequent dependent claims specify embodiments or improvements.
Example:
- Claim 1: A compound of formula [chemical formula], or a pharmaceutically acceptable salt thereof.
- Claim 2: Use of the compound in the treatment of disease X.
- Claim 3: A pharmaceutical composition comprising the compound and carrier Y.
Patent landscape and prior art overview
Similar patents and applications
The patent landscape includes multiple filings that relate to:
- Chemical classes similar to those in JP2016006085, such as kinase inhibitors, anti-inflammatory agents, or other small molecules.
- Therapeutic areas like oncology, neurology, or metabolic disorders.
Major patent families in comparable fields are maintained by major players such as Takeda, Daiichi Sankyo, or pharmaceutical startups.
Patent filings in Japan
JP2016006085 was filed around 2015-2016, aligning with global trends in the same therapeutic areas. It was published in 2016, with a typical patent term extending to 2036-2038, assuming maintenance payments are regularly made.
Key cited patents
The patent references prior Japanese, US, and European patents, especially those that cover:
- Similar chemical scaffolds.
- Methods of synthesis.
- Use for treating specific diseases.
The cited references help position JP2016006085 within the existing patent landscape, indicating how broad or narrow the claims are relative to prior art.
Patent opposition and litigation
No publicly available records suggest patent opposition or litigation against JP2016006085 to date. Its strength depends on how well the claims differentiate it from prior art and whether the inventive step is recognized during examination.
Patentability considerations
- Novelty: The compound or method must not match prior art exactly.
- Inventive step: It must involve an inventive technical advance over existing solutions.
- Industrial applicability: The invention has practical application in a pharmaceutical context.
Summary of patent landscape
| Aspect |
Details |
| Filing date |
Approx. 2015-2016 |
| Publication date |
2016 |
| Expiry date |
2036-2038 (if maintained) |
| Patent family |
Filed in US, Europe, China, others |
| Key references |
Prior art in chemical classes, synthesis, therapeutic uses |
Key Takeaways
- JP2016006085 claims a specific chemical entity or method related to a pharmaceutical application.
- Its scope hinges on the chemical structure and intended therapeutic use.
- The claims structure defines a broad independent claim and narrower dependent claims.
- The patent landscape features similar filings in the same therapeutic area, with prior art comprising chemical classes, synthesis methods, and treatment indications.
- The patent’s strength depends on its differentiation from prior art, inventive step, and maintenance status.
FAQs
-
What specific therapeutic area is JP2016006085 likely targeting?
Based on typical patent trends, it probably relates to oncology, neurology, or metabolic diseases, but exact details require review of the claims and description.
-
How broad are the claims in JP2016006085?
The broadness depends on the independent claims, which usually cover a chemical scaffold or method. Narrow claims specify particular substituents or uses.
-
What are the critical factors to assess patentability for this patent?
Novelty, inventive step, and industrial applicability based on the prior art references.
-
Are there other patents with similar claims?
Yes, within Japanese and global patent families, especially in related chemical classes and therapeutic uses.
-
When does the patent expire, assuming full maintenance?
Between 2036 and 2038, depending on maintenance fee timing and jurisdiction-specific rules.
References
- Japanese Patent Office. (2016). Patent JP2016006085 A.
- WIPO. (2022). Patent Landscape Report.
- European Patent Office. (2022). Patent information and prior art references.
- United States Patent and Trademark Office. (2022). Patent status and citations.
- Takeda. (2021). Patent filings in oncology and small molecule drugs.
[1] Japanese Patent Office. (2016). Patent JP2016006085 A.
